ReviewEuropean cardiology2026
Frailty Meets Cardio-oncology: A New Frontier in Personalised Cancer Care.
Review in European cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Frailty in older patients with cancer in Vietnam.BMC geriatrics · 2026Observational
- Enhancing Cardiovascular Care in Frailty: Priorities for Future Research.European cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, novel cancer therapies have significantly improved patient survival, but they have also introduced clinical challenges, particularly regarding treatment-related cardiovascular toxicity. Frailty is a clinical syndrome characterised by reduced physiological reserve, and is associated with poorer clinical outcomes and an elevated risk of cardiovascular disease. While it is more prevalent among older adults, frailty can also affect cancer patients due to shared pathophysiological mechanisms, such as mitochondrial dysfunction, chronic inflammation and oxidative stress, which may contribute to cancer therapy-induced cardiac damage. However, evidence supporting frailty as a predictive factor for cardiovascular complications in the cardio-oncology setting remains limited. This review emphasises the importance of incorporating frailty assessment into the oncological setting to improve risk stratification and guide personalised therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.